Departed
Eeva Hakoranta
Chief Licensing Officer
IDCC ·
InterDigital, Inc.
Effective April 4, 2025, Eeva Hakoranta will no longer be serving as Chief Licensing Officer.
Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7851–7900 of 76387
Effective April 4, 2025, Eeva Hakoranta will no longer be serving as Chief Licensing Officer.
On April 2, 2025, Robert C. Griffin, a director of the Company since July 2005, and current Chairman of the Board of the Company, informed the Company that he will be retiring from the Board of the Company, without standing for re-election at the 2025 Annual Meeting of Stockholders.
On March 31, 2025, the majority voting stockholder of General Enterprise Ventures, Inc. (the “Corporation”) approved the appointment of the following persons as members of the Board of Directors (the “Board”) of the Corporation, effective April 1, 2025: Theodore Ralston Jeffrey Pomerantz John Costa
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the majority voting stockholder of General Enterprise Ventures, Inc. (the “Corporation”) approved the appointment of the following persons as members of the Board of Directors (the “Board”) of the Corporation, effective April 1, 2025: Theodore Ralston Jeffrey Pomerantz John Costa
On March 31, 2025, the Board of the Corporation approved the appointment of the following persons as officers (each, an “Officer” and collectively, the “Officers”) of the Corporation, effective April 1, 2025: Theodore Ralston President and Chief Executive Officer Nanuk Warman Secretary and Chief Financial Officer Joshua Ralston Vice President of Operations Anthony Newton General Counsel
On March 31, 2025, the majority voting stockholder of General Enterprise Ventures, Inc. (the “Corporation”) approved the appointment of the following persons as members of the Board of Directors (the “Board”) of the Corporation, effective April 1, 2025: Theodore Ralston Jeffrey Pomerantz John Costa
On April 4, 2025, Kenneth M. Greenwood, Chief Product Architect, notified Healthcare Integrated Technologies, Inc. (the “Company”) of his resignation from all positions with the Company, effective immediately.
On March 31, 2025, Michael R. Edwards notified Caleres, Inc. (the “Company”) of his decision to resign as the Company’s Division President – Famous Footwear, effective May 2, 2025.
On April 1, 2025 , the Board of Directors (the “Board”) of Nordstrom, Inc. appointed the Corporation’s Vice President – Controller, Randy Kanai, age 50, to the position of Interim Chief Accounting Officer.
Retirement of Gerald Ng: Gerald Ng, Vice President and Chief Financial Officer of Data I/O Corporation (the “Company”), announced his planned retirement and upcoming transition, which is expected to take place in the second quarter of 2025.
appointed Kevin D. Chapman, Renasant’s President and Chief Operating Officer and a member of the Bank Board, to fill this new seat on the Board
Kevin D. Chapman assuming the role of the Company’s and the Bank’s Chief Executive Officer on the Transition Date (as previously disclosed)
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
appointed each of M. Ray (Hoppy) Cole, Jr., Jonathan A. Levy, Renee Moore, and Ted E. Parker to fill the new seats on the Board, effective as of the Effective Time
E. Robinson McGraw, the Company’s Executive Chairman and the Chairman of the Board and of the Bank Board, agreed with the Company that he would resign as an officer and employee of the Company and the Bank, effective May 1, 2025 (the “Transition Date”)
Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani.
On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025.
On April 1, 2025, the Company appointed Scott Garula, currently President of Cintas’ Rental Division, to succeed Mr. Hansen as Executive Vice President & CFO, effective June 1, 2025.
J. Michael Hansen notified Cintas Corporation (the “Company”) of his intent to retire from his role as Executive Vice President & Chief Financial Officer (“CFO”).
on March 18, 2025, the Board approved, effective on April 1, 2025, (i) the removal of Thomas Krywe as interim Chief Financial Officer, principal financial officer and principal accounting officer of the Company and (ii) the appointment of Alison Engel as Chief Financial Officer, principal financial officer and principal accounting officer of the Company.
on March 18, 2025, the Board approved, effective on April 1, 2025, (i) the removal of Thomas Krywe as interim Chief Financial Officer, principal financial officer and principal accounting officer of the Company and (ii) the appointment of Alison Engel as Chief Financial Officer, principal financial officer and principal accounting officer of the Company.
Kathy Vrabeck retired from the Company as its Chief Operating Officer, effective as of April 1, 2025.
On April 3, 2025, Paul L. Berns informed the Board of Directors (the “Board”) of UNITY Biotechnology, Inc. (“Unity” or the “Company”) of his resignation as a member of the Board of the Company, and all of the committees of the Board on which he serves, in each case, effective at the close of business on April 4, 2025.
pursuant to which Mr. Wilson resigned as an employee of the Company, effective April 1, 2025
Each of Ramesh Gopalakrishnan and Jeffrey S. McCreary notified the Board of Directors (the “Board”) of Benchmark Electronics, Inc. (the “Company”) on April 2, 2025 and April 3, 2025, respectively, of his intent not to stand for re-election at the Company’s 2025 annual meeting of shareholders to be held on May 14, 2025 (the “Meeting”) upon the expiration of his term.
Each of Ramesh Gopalakrishnan and Jeffrey S. McCreary notified the Board of Directors (the “Board”) of Benchmark Electronics, Inc. (the “Company”) on April 2, 2025 and April 3, 2025, respectively, of his intent not to stand for re-election at the Company’s 2025 annual meeting of shareholders to be held on May 14, 2025 (the “Meeting”) upon the expiration of his term.
the Board has nominated Glynis A. Bryan, retired Chief Financial Officer of Insight Enterprises, Inc. (NASDAQ:NSIT), for election to the Board at the Meeting.
On April 2, 2025, the Company and its President, L. Jay Cross, mutually agreed not to renew Mr. Cross’ employment agreement upon the expiration of its current term on December 1, 2025, which shall be treated as a non-renewal by the Company under his employment agreement.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
the directors of Merger Sub immediately prior to the Effective Time, which consisted of Telukutla Venkata Nasara Reddy and Katherine Dunn, became the directors of the surviving corporation.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
the following persons became officers of the Company: Telukutla Venkata Nasara Reddy, Brad Debold and Katherine Dunn.
the directors of Merger Sub immediately prior to the Effective Time, which consisted of Telukutla Venkata Nasara Reddy and Katherine Dunn, became the directors of the surviving corporation.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
the following persons became officers of the Company: Telukutla Venkata Nasara Reddy, Brad Debold and Katherine Dunn.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
As of the Effective Time, all directors of the Company serving as of immediately prior to the Effective Time, consisting of James B. Miller, Jr., Allan Dow, W. Dennis Hogue, Matthew G. McKenna, Celena Matlock, Thomas L. Newberry, V., Lizanne Thomas, and Nicole Wu, resigned from the board of directors of the Company including any committees thereof on which they served.
the following persons became officers of the Company: Telukutla Venkata Nasara Reddy, Brad Debold and Katherine Dunn.
increased the size of the Board from eight to nine directors and appointed Wayde McMillan as a director of the Company, effective April 4, 2025.
appointed Wayde McMillan as a director of the Company, effective April 4, 2025.
the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025
Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.